DSIP prices

FROM PEPTIDES CALCULATOR

About DSIP

Source profile reviewed 2026-10-01 · Imported 2026-10-22. Read the full compound profile

DSIP (delta sleep-inducing peptide) is a nine-residue peptide that Guido Schoenenberger and Marcel Monnier's group isolated from the cerebral venous blood of rabbits in 1977 and named for the delta wave sleep it produced when infused into other animals. Every published human study used slow intravenous infusion: a handful of small sleep-laboratory investigations in Switzerland, Uruguay and the Netherlands that disagreed about whether it changed sleep at all, open-label series in alcohol and opiate withdrawal, and a seven-patient pilot in chronic pain. The FDA evaluated emideltide, the compounding name for DSIP, in 2026 and reported an animal plasma half-life under 10 minutes, no pharmacokinetic or safety data for the subcutaneous route that vendors sell, and insufficient evidence of effectiveness for insomnia, narcolepsy or opioid withdrawal. The nominations to allow compounding with it were withdrawn, an April 2026 update moved it from the agency's Category 2 safety-risk table into a list of withdrawn nominations, and FDA then proposed that neither the free base nor the acetate be added to the 503A Bulks List. It is approved nowhere and has never been the subject of a registered trial.

Formula

C35 H48 N10 O15

Molar mass

848.8 g/mol

CAS number

62568-57-4

Amino acids

9

Research evidence described in the source

Limitations noted in the source

• Individual claims and source links have not yet completed editorial verification.
• Evidence level, applicable study model, formulation, route and population remain unassigned.

Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.